| (Values in U.S. Thousands) | Jan, 2026 | Jan, 2026 | Jan, 2026 | Jan, 2026 | Jan, 2026 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 0 | 0 | 0 | 0 | 0 |
| Net Income Growth | unch | unch | unch | unch | unch |
Ono Pharmaceutical (OPHLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
ONO Pharmaceutical Co., Ltd., was incorporated in Japan on July 4, 1947. The Company along with its subsidiaries is engaged in research & development, manufacturing and selling of medical and general pharmaceutical products. Its product portfolio includes GLACTIV Tablets for the Treatment of Type 2 Diabetes; RECALBON Tablets for the Treatment of Osteoporosis; EMEND Capsules / PROEMEND for Intravenous Injection for the Treatment of Chemotherapy-induced Nausea and Vomiting, STAYBLA Tablets for the Treatment of Overactive Bladder; RIVASTACH Patch for the Treatment of Alzheimer's Disease; ORENCIA for Subcutaneous Injection for the Treatment of Rheumatoid Arthritis; FORXIGA Tablets for the Treatment of Type 2 Diabetes; OPALMON Tablets for the Treatment of Peripheral Circulatory Disorder; ONOACT for Intravenous Infusion for the Treatment of Tachyarrhythmia Intra-operative or Post-operative, or Tachyarrhythmia in Left Ventricular Dysfunction; and ELASPOL for Injection for the Treatment of Acute Lung Injury Associated with Systemic Inflammatory Response Syndrome. The Company has operations in geographical areas including; Japan, Europe, and Asia.